{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-22-000013","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.536657+00:00","generated_at":"2026-06-21T23:05:21.524332+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"vTv Therapeutics Q3 net loss widens to $4.3M; appoints new CEO, plans Phase 3 for TTP399","bullets":["Net loss of $4.3M ($0.05/share) vs. $1.1M loss a year ago, driven by higher R&D and G&A costs.","Appointed Paul Sekhri as President & CEO effective August 1, 2022, succeeding prior leadership.","CinRx Pharma subsidiary to invest $10M in common stock and provide collaboration for TTP399 trials.","Cash position $15.3M as of Sept 30, 2022, up from $13.4M at year-end 2021.","Company plans two pivotal Phase 3 trials of TTP399 for type 1 diabetes starting Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-22-000013","json":"https://secwatch.observer/filing/0001641489-22-000013.json","markdown":"https://secwatch.observer/filing/0001641489-22-000013.md","text":"https://secwatch.observer/filing/0001641489-22-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148922000013/0001641489-22-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148922000013/vtvt-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:05:21.524332+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f44cf617500c7bbe24c0db7b4fca49c311581053","claim":"vTv Therapeutics Inc. reported the third quarter ended September 30, 2022 results: net income $4.3 million or $0.05 per basic share, EPS $0.05 per basic share.","evidence_excerpt":"Net loss attributable to vTv shareholders for the three months ended September 30, 2022, was $4.3 million or $0.05 per basic share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148922000013/0001641489-22-000013-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$4.3 million or $0.05 per basic share"},{"label":"EPS","value":"$0.05 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}